Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
← catalyst calendarNCT06233942 · readout in 404 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
308estimated
Sites
37
Countries
Australia, Brazil, China +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-12 | actual | When the study began enrolling |
| Primary completion | 2027-09-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumor
Interventions
- Drug: BG-C9074
- Drug: Tislelizumab
- Drug: Bevacizumab
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Approximately 3 years
Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-C9074
measured Approximately 18 months
Phase 1a: Recommended Dose for Expansion (RDFE) of BG-C9074.
measured Approximately 18 months
Phase 1b: Overall Response Rate (ORR) as monotherapy and in combination with tislelizumab
measured Approximately 3 years
Phase 1b: Recommended Phase 2 dose (RP2D) of BG-C9074 as monotherapy and in combination with bevacizumab or tislelizumab
measured Approximately 30 months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed